Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

Etravirine Matches Efavirenz Effectiveness with Fewer Side Effects

The next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (Intelence) worked as well as the widely-used NNRTI efavirenz (Sustiva, also in the Atripla combination pill) but with fewer central nervous system side effects, researchers reported in the August 30, 2011, advance online edition of AIDS.alt

Read more:

FDA Approves Complera, New Single-Pill Regimen for HIV

The U.S. Food and Drug Administration today approved a new once-daily all-in-one pill for treatment-naive people with HIV containing tenofovir/emtricitabine/rilpivirine, to be marketed under the brand name Complera.alt

Read more:

IAS 2011: HIV NNRTI Rilpivirine Effective and Well-Tolerated at 2 Years

The recently approved next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant) continued to show efficacy comparable to efavirenz (Sustiva) at 96 weeks, but with fewer central nervous system side effects and a more favorable lipid profile in the Phase 3 ECHO and THRIVE trials. alt

Read more:

IAS 2011: Maraviroc Improves Liver Fibrosis in HIV/Hepatitis C Coinfected Patients

Treatment with maraviroc is associated with the regression of liver fibrosis in HIV-positive patients co-infected with hepatitis C, a small randomised study presented to the Sixth International AIDS Society conference (IAS 2011) in Rome shows.alt

Read more:

IAS 2011: NRTI-Sparing Regimens Do Well in Treatment-Naive Patients

A nucleoside-sparing regimen based on raltegravir (Isentress) and ritonavir-boosted darunavir (Prezista) is as safe and effective as a traditional nucleoside-based HIV treatment combination, according to the results of a small US study presented to the 6th Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) in Rome. alt

Read more: